LentiGlobin BB305 gene therapy: Phase III started

bluebird began the international Phase III HGB-207 trial to evaluate LentiGlobin BB305 in 15 patients with non-beta-0/beta-0 genotypes. bluebird expects the trial to be confirmatory in the EU. Last year, the company said it would seek conditional approval of LentiGlobin BB305 in the EU based on 2 Phase I/II trials. ...